Multiple sclerosis (MS) is a disease that affects the brain and spinal cord. In 2025, doctors and scientists are starting to focus on a new way to treat it—not just by managing symptoms, but by actually trying to repair the damage it causes.
One key part of this damage happens to a layer called myelin. Myelin is like a protective cover around nerves, and in people with MS, it gets damaged. Fixing this cover is called remyelination, and it’s becoming a big focus in MS research.
What Is Quantum BioPharma Doing?
Quantum BioPharma (NASDAQ: QNTM | CSE: QNTM) is a company working on a new treatment called Lucid-MS. This treatment is being developed to help protect and repair the myelin layer, not just stop the immune system from attacking it.
Most current MS drugs work by calming down the immune system. Lucid-MS takes a different approach—it’s designed to help the body heal the nerves themselves. In lab tests, it showed it could protect the myelin and stop it from breaking down.
Lucid-MS has already passed its first safety trial, and the company is planning the next steps, depending on approval from health regulators. Scientists from a hospital connected to Harvard helped develop this treatment, adding strong research support.
Why This Matters Now
MS affects millions of people worldwide, and the market for MS treatments is expected to grow a lot—from $27 billion in 2024 to more than $46 billion by 2033. As new ways to diagnose MS earlier become available, the need for better treatments is also growing.
Lucid-MS is arriving at just the right time. While some companies are still focused on calming the immune system, Quantum is aiming to repair the damage already done. This makes Lucid-MS stand out.
Experts Agree: Fixing Myelin Is the Future
Top doctors, like Dr. Daniel Ontaneda from the Cleveland Clinic, believe that helping the body fix damaged nerves is the next big step in treating MS. Other companies are working on similar treatments, but very few have shown strong early data like Lucid-MS.
Looking Ahead
As the medical world focuses more on healing MS, Quantum BioPharma and Lucid-MS are right in the middle of the action—working toward a future where patients may not just live with MS, but recover from it.
Source: https://www.neurologylive.com/view/repair-remyelination-progress-what-driving-ms-innovation-2025-
Visit $QNTM HUB On AGORACOM : https://agoracom.com/ir/Quantumbiopharma
Visit $QNTM 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Quantumbiopharma/profile
Visit $QNTM Official Verified Discussion Forum On AGORACOM:
DISCLAIMER AND DISCLOSURE
This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)
AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) . As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post. You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients. In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.
Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations. These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.